Making a Differential Diagnosis of Low-Grade Serous Ovarian Cancer
Expert oncologist Ian Hagemann, MD, PhD, shares insight into the process of making a differential diagnosis of low-grade serous ovarian cancer in light of adjacent disease and available IHC testing.
HRD Testing in Ovarian Cancer: Clinical Guidelines Recommendations
Panelists discuss clinical guidelines recommendations for HRD testing in ovarian cancer and how they inform their practice.
Leveraging HRD Testing Results in Ovarian Cancer: Clinical Data
Discussion centered around data from the PAOLA-1 trial, highlighting the prevalence of BRCA1/2 mutations and HRD status in ovarian cancer, and how patients with these alterations may benefit from PARP inhibitor treatment.
HRD Tests for Ovarian Cancer
The panel reviews commercially available HRD tests and expand upon factors that may influence test choice, such as clinical performance, institutional availability, turnaround time, and cost.
Other Causes of HRD: Chromosomal LOH, LST, and TAI
Dr Hagemann explains how loss of heterozygosity (LOH), large-scale state transitions (LSTs), and telomeric allelic imbalance (TAI) can also contribute to HRD.
Defining HRD and its Role in Ovarian Cancer
Experienced clinicians explain the role of the homologous recombination repair (HRR) pathway in DNA repair and how mutations in HRR-related genes, including BRCA1 and BRCA2, can cause homologous recombination deficiency (HRD) and contribute to the development and progression of ovarian cancer (OC).
Opening Remarks from Dr. Herzog, Dr. Krivak, and Dr. Hagemann
Thomas Herzog, MD, Thomas Krivak, MD, and Ian Hagemann, MD, PhD open their discussion by introducing themselves and the objectives of the program.
Dr. Hagemann on Best Practices for Pathology in Gynecologic Cancers
Ian Hagemann, MD, PhD, discusses the main take home from his presentation at the 2020 SGO Winter Meeting.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512